Update on the Management of Mucositis
3/30/2008 Ketchum, ID staff CancerConsultants.com Introduction The fact that mucositis remains an important toxicity of cancer therapy was reflected in the thirty abstracts dealing with this topic that were included in this year’s MASCC/ISOO symposium. While mucositis has most often been associated with damage to the oral cavity, it is clear that its clinical and scientific import to the rest of the gastrointestinal tract is significant. Abstracts presented fell into a range of topics that spanned preclinical mechanistic studies to interventional clinical trials. Among the major subject categories addressed were techniques and instruments to assess mucositis and observational reports of its behavior, incidence and risk, animal and human studies of the biological basis for mucositis, the burden of illness of mucositis, and clinical trials of specific interventions. Mucositis Assessment, Incidence, Risk Factors, and Burden A number of studies reported on the assessment of mucositis, its incidence, risk factors, and impact on quality of life, health, and economic outcomes. Dudley, et al. reported the application of an innovative statistical approach to quantify parameters of change for patient populations, model individual variability about population parameters, and predict which patients would be most severely affected. Their approach, known as Latent Growth Curve Analysis (LGCA), was applied to estimate parameters of change in erythema in 133 HSCT patients treated with high-dose chemotherapy conditioning regimens. Clinical ratings of erythema from the 20 item Oral Mucositis Index were made 8 times over a 3-week period. The model identified statistically significant individual variability relative to the average [...]